. 2020 May 18;6(2):66. doi: 10.3390/jof6020066

Table 1.

Overview of in vivo data obtained from murine models and clinical trials.

Study	Treatment Regimen	Main Results				Reference
*Murine model of*
• systemic candidiasis	CAmB vs. DAmB	• 100% survival at CAmB 0.5 mg/kg/day equivalent to DAmB 2 mg/kg/day.				[10]
• systemic candidiasis	CAmB vs. DAmB	• dose-dependent reduction of CFU in kidney and lungs.				[10]
• cryptococcal meningitis	CAmB + 5FC vs. DAmB + 5FC	• CAmB 25 mg/kg/day + 5FC equivalent to DAmB 5 mg/kg/day + 5FC.				[17]
• cryptococcal meningitis	CAmB + 5FC vs. DAmB + 5FC	• Comparable brain tissue levels between CAmB and DAmB.				[17]
• invasive aspergillosis	CAmB vs. DAmB	• Dose dependent reduction of CFU and mortality.				[16]
• invasive aspergillosis	CAmB vs. DAmB	• Survival rate of 70% at CAmB 20 and 40 mg/kg/day.				[16]
Clinical trials
• Phase IIA, CMC	CAmB	• Improvement of symptoms in 50%–85% at CAmB 400–800 mg.				[19]
		• AE: nausea, dizziness.
		• No organ disorders.
• Phase II, VVC	CAmB vs. fluconazole		CAmB 200 mg	CAmB 400 mg	Fluconazole 150 mg	[20]
		Clinical cure	52 %	55 %	75 %
		Mycological response	36 %	32 %	84 %
		Overall response	16 %	14 %	69 %
		non-serious AE	22 %	27 %	9 %

CAmB, encochleated amphotericin b (MAT2203); DAmB, amphotericin deoxycholate; CFU, colony forming unit; 5FC, flucytosine; CMC, chronic mucocutaneous candidiasis; VVC, vulvovaginal candidiasis; AE, adverse events.